Loading...
SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
Introduction: Immune checkpoint inhibitors (ICPi) are used to augment the immune response and have led to improved outcomes in various malignancies. With this enhanced immunologic response comes a spectrum of side effects, known as immune-related adverse events (iRAEs). These are most commonly derma...
Na minha lista:
| Udgivet i: | J Endocr Soc |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Endocrine Society
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553242/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-170 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|